miRagen Therapeutics and Signal Genetics Sign Merger Agreement -Merger to create clinical-stage, NASDAQ-listed, biopharmaceutical company developing proprietary micro RNA-targeted therapeutics - -Concurrent financing of $40 million from Miragen...Sign Merger Agreement • November 1st, 2016 • Signal Genetics, Inc. • Services-medical laboratories
BOULDER, CO and CARLSBAD, CA – Signal Genetics, Inc. (Nasdaq: SGNL) (“Signal”) and Miragen Therapeutics, Inc. (“miRagen”), a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of miRagen are currently estimated to become holders of approximately 96% of Signal’s outstanding common stock on a fully-diluted basis. The proposed merger remains subject to certain conditions, including approval by Signal’s and miRagen’s stockholders.
